Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA
17. Mai 2018 12:47 ET
|
Exosome Diagnostics
Waltham, MA, May 17, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics’ novel urine-based prostate cancer liquid biopsy biomarker test, ExoDx™ Prostate(IntelliScore) or EPI, was selected out of 3000...